Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 18:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. ...
February 06, 2026 06:44 ET | Source: AstuteAnalytica India Pvt. Ltd.

Opioid Withdrawal Syndrome (OWS) Market to Reach US$ 2,633.4 Million by 2030 Driven by Rising Opioid Use Disorder and Expansion of Medication-Assisted Treatment Programs | Astute Analytica

Chicago, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The global opioid withdrawal syndrome (OWS) market was valued at 1,068.3 million in 2021 and is expected to reach US$ 2,633.4 million by 2030, growing at a...
February 05, 2026 13:34 ET | Source: FFF Enterprises.com

ODRescue™ Launches a Community-Supported Naloxone Locator Map, Making It Free for States, Schools, and Businesses

TEMECULA, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ODRescue™, a program dedicated to expanding on-demand access to life-saving products and sponsored by FFF Enterprises, Inc.— the nation’s most...
February 03, 2026 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million ...
January 28, 2026 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding...
January 14, 2026 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...
January 14, 2026 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN®...
January 12, 2026 11:29 ET | Source: Research and Markets

Naloxone Hydrochloride (CAS 357-08-4) Industry Research Report 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The "Naloxone Hydrochloride (CAS 357-08-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added...
December 31, 2025 12:23 ET | Source: Cook County Health

Cook County Health Looks Back on 2025

Chicago, IL, Dec. 31, 2025 (GLOBE NEWSWIRE) -- As the New Year approaches, Cook County Health proudly reflects on a successful 2025 marked by progress, innovation, and a deepened commitment to its...
December 22, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...